IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v15y2014i4p353-362.html
   My bibliography  Save this article

Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain

Author

Listed:
  • Carole Dembek
  • Leigh White
  • Jayson Quach
  • Andrea Szkurhan
  • Nazia Rashid
  • M. Blasco

Abstract

In our cost-effectiveness analysis of first-line injectable DMTs in Spain, we found IM IFNβ-1a to be more cost-effective than SC IFNβ-1a, IFNβ-1b or GA. Sensitivity analyses confirmed the robustness of these results. Copyright Springer-Verlag Berlin Heidelberg 2014

Suggested Citation

  • Carole Dembek & Leigh White & Jayson Quach & Andrea Szkurhan & Nazia Rashid & M. Blasco, 2014. "Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(4), pages 353-362, May.
    • Handle: RePEc:spr:eujhec:v:15:y:2014:i:4:p:353-362
    DOI: 10.1007/s10198-013-0478-z
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s10198-013-0478-z
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s10198-013-0478-z?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Gisela Kobelt & J. Berg & P. Lindgren & G. Izquierdo & O. Sánchez-Soliño & J. Pérez-Miranda & M. Casado, 2006. "Costs and quality of life of multiple sclerosis in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 65-74, July.
    2. Gisela Kobelt & J. Berg & P. Lindgren & G. Izquierdo & O. Sánchez-Soliño & J. Pérez-Miranda & M. Casado, 2006. "Costs and quality of life of multiple sclerosis in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(02), pages 65-74, July.
    3. Stephanie Earnshaw & Jonathan Graham & MerriKay Oleen-Burkey & Jane Castelli-Haley & Kenneth Johnson, 2009. "Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis," Applied Health Economics and Health Policy, Springer, vol. 7(2), pages 91-108, June.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. A. J. Hawton & C. Green, 2016. "Multiple sclerosis: relapses, resource use, and costs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(7), pages 875-884, September.
    2. Olivia Ernstsson & Hanna Gyllensten & Kristina Alexanderson & Petter Tinghög & Emilie Friberg & Anders Norlund, 2016. "Cost of Illness of Multiple Sclerosis - A Systematic Review," PLOS ONE, Public Library of Science, vol. 11(7), pages 1-25, July.
    3. Gisela Kobelt & Jenny Berg & Peter Lindgren & M. Battaglia & C. Lucioni & A. Uccelli, 2006. "Costs and quality of life of multiple sclerosis in Italy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 7(2), pages 45-54, July.
    4. Oleguer Parés-Badell & Gabriela Barbaglia & Petra Jerinic & Anders Gustavsson & Luis Salvador-Carulla & Jordi Alonso, 2014. "Cost of Disorders of the Brain in Spain," PLOS ONE, Public Library of Science, vol. 9(8), pages 1-10, August.
    5. Matthew Sussman & Jeffrey C. Yu & Joseph Menzin, 2020. "Do Research Groups Align on an Intervention’s Value? Concordance of Cost-Effectiveness Findings Between the Institute for Clinical and Economic Review and Other Health System Stakeholders," Applied Health Economics and Health Policy, Springer, vol. 18(4), pages 477-489, August.
    6. B. Rodríguez-Sánchez & S. Daugbjerg & L. M. Peña-Longobardo & J. Oliva-Moreno & I. Aranda-Reneo & A. Cicchetti & J. López-Bastida, 2023. "Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(2), pages 247-277, March.
    7. Sergio Iannazzo & Ange-Christelle Iliza & Louise Perrault, 2018. "Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies," PharmacoEconomics, Springer, vol. 36(2), pages 189-204, February.

    More about this item

    Keywords

    Multiple sclerosis; Cost-effectiveness; Disease-modifying therapies; Interferon-beta; I1;
    All these keywords.

    JEL classification:

    • I1 - Health, Education, and Welfare - - Health

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:15:y:2014:i:4:p:353-362. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.